0% found this document useful (0 votes)
44 views

Fact-Sheet Syngene

- Syngene International Limited is an Indian biotechnology company that provides research and manufacturing services to pharmaceutical companies. - According to its balance sheet and profit and loss statements for the first quarter of fiscal year 2022, Syngene saw increases in revenue, EBITDA, and profit after tax compared to the same period last year but decreases compared to the previous quarter. - Key financial highlights include a 41% increase in revenue year-over-year and a 33% increase in profit after tax for the first quarter of 2022, but a 10% decrease in revenue and 52% decrease in profit for the quarter compared to the previous quarter.

Uploaded by

Rahul Sharma
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
44 views

Fact-Sheet Syngene

- Syngene International Limited is an Indian biotechnology company that provides research and manufacturing services to pharmaceutical companies. - According to its balance sheet and profit and loss statements for the first quarter of fiscal year 2022, Syngene saw increases in revenue, EBITDA, and profit after tax compared to the same period last year but decreases compared to the previous quarter. - Key financial highlights include a 41% increase in revenue year-over-year and a 33% increase in profit after tax for the first quarter of 2022, but a 10% decrease in revenue and 52% decrease in profit for the quarter compared to the previous quarter.

Uploaded by

Rahul Sharma
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 4

SYNGENE GROUP

FACT SHEET

June - 2021
SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)
BALANCE SHEET (Rs. Millions)
30 June 2021 31 March 2021
ASSETS

Non-current assets
Property, plant and equipment 20,653 20,322
Capital work-in-progress 2,109 2,372
Right-of-use assets 1,094 1,121
Investment property 366 376
Intangible assets 173 191
Financial assets
(i) Investments 2,710 2,787
(ii) Derivative assets 723 623
(iii) Other financial assets 819 1,038
Deferred tax assets (net) 898 891
Income tax assets (net) 866 867
Other non-current assets 363 177
Total non-current assets 30,774 30,765

Current assets
Inventories 1,315 596
Financial assets
(i) Investments 6,474 4,233
(ii) Trade receivables 3,982 3,392
(iii) Cash and cash equivalents 2,735 3,233
(iv) Bank Balances other than (iii) above 2,046 3,193
(v) Derivative assets 511 713
(vi) Other financial assets 780 1,704
Other current assets 1,191 1,003
Total Current assets 19,034 18,067

Total assets 49,808 48,832

EQUITY AND LIABILITIES


Equity
Equity share capital 4,008 4,000
Other equity 24,948 24,214
Total equity 28,956 28,214

LIABILITIES
Non - current liabilities
Financial liabilities
(i) Borrowings 5,203 5,124
(ii) Lease liabilities 1,046 1,052
(iii) Derivative liabilities 244 224
Provisions 545 520
Other non-current liabilities 2,329 2,368
Total non-current liabilities 9,367 9,288

Current liabilities
Financial liabilities
(i) Borrowings 2,639 2,599
(ii) Lease liabilities 154 154
(iii) Trade payables 2,779 2,416
(iv) Derivative liabilities 23 18
(v) Other financial liabilities 951 937
Provisions 494 465
Income tax liabilities (net) 146 134
Other current liabilities 4,299 4,607
Total current liabilities 11,485 11,330

Total equity and liabilities 49,808 48,832


SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)
PROFIT AND LOSS STATEMENT (Rs. Millions, except per share data)
Q1 Q1
Particulars FY 22 FY 21 Variance

INCOME
Revenue from operations 5,945 4,216 41%
Other income 123 153 -20%
Total Revenue 6,068 4,369 39%

EXPENDITURE
Material and power costs 2,082 1,019 104%
Staff costs 1,711 1,404 22%
Foreign exchange (net) (154) 33 -567%
Other expenses 656 515 27%
Material, power, staff, forex and other expenses 4,295 2,971
EBITDA 1,773 1,398 27%
Finance costs 79 74 7%
Depreciation and amortisation expenses 747 661 13%
Profit before tax 947 663 43%
Tax on above 174 83
Profit after tax 773 580 33%
EPS - Basic (not annualised) 1.91 1.47
EPS - Diluted (not annualised) 1.89 1.46
SYNGENE INTERNATIONAL LIMITED (CONSOLIDATED)
PROFIT AND LOSS STATEMENT (Rs. Millions, except per share data)
Q1 Q4
Particulars FY 22 FY 21 Variance

INCOME
Revenue from operations 5,945 6,586 -10%
Other income 123 184 -33%
Total Revenue 6,068 6,770 -10%

EXPENDITURE
Material and power costs 2,082 1,762 18%
Staff costs 1,711 1,826 -6%
Foreign exchange (net) (154) (47) 228%
Other expenses 656 891 -26%
Material, power, staff, forex and other expenses 4,295 4,432
EBITDA 1,773 2,338 -24%
Finance costs 79 66 20%
Depreciation and amortisation expenses 747 700 7%
Profit before tax and exceptional item 947 1,572 -40%
Tax on above 174 194 -10%
Profit after tax before exceptional item 773 1,378 -44%
Exceptional item, net of taxes - 228
Profit for the period 773 1,606 -52%
EPS - Basic (not annualised) 1.91 4.04
EPS - Diluted (not annualised) 1.89 4.01

You might also like

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy